Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 4
2001 5
2002 15
2003 50
2004 57
2005 76
2006 105
2007 109
2008 152
2009 113
2010 111
2011 133
2012 151
2013 153
2014 177
2015 142
2016 134
2017 112
2018 103
2019 83
2020 83
2021 104
2022 74
2023 47
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

2,075 results

Results by year

Filters applied: . Clear all
Page 1
Atazanavir.
Goldsmith DR, Perry CM. Goldsmith DR, et al. Drugs. 2003;63(16):1679-93; discussion 1694-5. doi: 10.2165/00003495-200363160-00003. Drugs. 2003. PMID: 12904086 Review.
Atazanavir is a novel azapeptide protease inhibitor with high specificity for, and activity against, HIV-1 protease. ...Atazanavir has a pharmacokinetic profile that allows for once-daily oral administration. ...
Atazanavir is a novel azapeptide protease inhibitor with high specificity for, and activity against, HIV-1 protease. ...Atazanavir …
Atazanavir Resensitizes Candida auris to Azoles.
Elgammal Y, Salama EA, Seleem MN. Elgammal Y, et al. Antimicrob Agents Chemother. 2023 May 17;67(5):e0163122. doi: 10.1128/aac.01631-22. Epub 2023 Apr 24. Antimicrob Agents Chemother. 2023. PMID: 37092991 Free PMC article.
Candida auris represents an urgent health threat. Here, we identified atazanavir as a potent drug capable of resensitizing C. auris clinical isolates to the activity of azole antifungals. Atazanavir was able to significantly inhibit the efflux pumps, glucose transpo …
Candida auris represents an urgent health threat. Here, we identified atazanavir as a potent drug capable of resensitizing C. auris c …
Atazanavir: new option for treatment of HIV infection.
Havlir DV, O'Marro SD. Havlir DV, et al. Clin Infect Dis. 2004 Jun 1;38(11):1599-604. doi: 10.1086/420932. Epub 2004 May 13. Clin Infect Dis. 2004. PMID: 15156449 Review.
Atazanavir (400 mg) can be administered once per day and requires only 2 capsules. ...In treatment-experienced patients with high-level resistance to other protease inhibitors, susceptibility to atazanavir is usually reduced, and optimal effects of atazanavir …
Atazanavir (400 mg) can be administered once per day and requires only 2 capsules. ...In treatment-experienced patients with high-lev …
Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Antunes F. Antunes F. Expert Rev Anti Infect Ther. 2017 Jun;15(6):569-576. doi: 10.1080/14787210.2017.1323634. Epub 2017 May 9. Expert Rev Anti Infect Ther. 2017. PMID: 28443391 Review.
Pharmacokinetics boosting of protease inhibitor allows a higher genetic barrier, as few or no drug-resistant mutations are detected in patients with virologic failure. Areas covered: Atazanavir sulfate + cobicistat (ATV/c) was recently approved for the treatment of …
Pharmacokinetics boosting of protease inhibitor allows a higher genetic barrier, as few or no drug-resistant mutations are detected in patie …
Atazanavir for the treatment of human immunodeficiency virus infection.
Busti AJ, Hall RG, Margolis DM. Busti AJ, et al. Pharmacotherapy. 2004 Dec;24(12):1732-47. doi: 10.1592/phco.24.17.1732.52347. Pharmacotherapy. 2004. PMID: 15585441 Review.
However, resistance to other protease inhibitors often confers clinically relevant resistance to atazanavir. Currently, atazanavir is not a preferred protease inhibitor for initial HAART regimens. ...Although hyperbilirubinemia is a common adverse drug reaction of …
However, resistance to other protease inhibitors often confers clinically relevant resistance to atazanavir. Currently, atazanavir …
Atazanavir: A novel once-daily protease inhibitor.
Piliero PJ. Piliero PJ. Drugs Today (Barc). 2004 Nov;40(11):901-12. doi: 10.1358/dot.2004.40.11.872579. Drugs Today (Barc). 2004. PMID: 15645003 Review.
Atazanavir was inferior to lopinavir/ritonavir in patients who previously failed an initial protease inhibitor containing regimen. Preliminary results in multiple PI-experienced patients indicate comparable efficacy to lopinavir/ritonavir in subjects receiving a boosted re …
Atazanavir was inferior to lopinavir/ritonavir in patients who previously failed an initial protease inhibitor containing regimen. Pr …
Atazanavir-Associated Crystalline Nephropathy.
Santoriello D, Al-Nabulsi M, Reddy A, Salamera J, D'Agati VD, Markowitz GS. Santoriello D, et al. Am J Kidney Dis. 2017 Oct;70(4):576-580. doi: 10.1053/j.ajkd.2017.02.376. Epub 2017 Jun 2. Am J Kidney Dis. 2017. PMID: 28579422
We describe a human immunodeficiency virus (HIV)-infected patient treated for 2 years with combination antiretroviral therapy including atazanavir (ATV). Kidney biopsy revealed a crystalline nephropathy associated with diffuse chronic and granulomatous interstitial inflamm …
We describe a human immunodeficiency virus (HIV)-infected patient treated for 2 years with combination antiretroviral therapy including a …
Atazanavir: improving the HIV protease inhibitor class.
Becker S. Becker S. Expert Rev Anti Infect Ther. 2003 Oct;1(3):403-13. doi: 10.1586/14787210.1.3.403. Expert Rev Anti Infect Ther. 2003. PMID: 15482137 Review.
Protease inhibitors are potent agents against HIV but their use is constrained by poor pharmacokinetics, cross-resistance and metabolic toxicities. Atazanavir [Reyataz] is a new protease inhibitors with once-daily dosing and minimal lipid and glycemic effects. ...Reversibl …
Protease inhibitors are potent agents against HIV but their use is constrained by poor pharmacokinetics, cross-resistance and metabolic toxi …
Atazanavir urolithiasis.
Chang HR, Pella PM. Chang HR, et al. N Engl J Med. 2006 Nov 16;355(20):2158-9. doi: 10.1056/NEJMc061892. N Engl J Med. 2006. PMID: 17108352 No abstract available.
Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia.
Dorresteijn MJ, Dekker D, Zwaag J, Heemskerk S, Roelofs HMJ, Smits P, van der Hoeven JG, Wagener FADTG, Pickkers P. Dorresteijn MJ, et al. Front Immunol. 2023 May 16;14:1176775. doi: 10.3389/fimmu.2023.1176775. eCollection 2023. Front Immunol. 2023. PMID: 37261364 Free PMC article.
However, its impact during acute inflammation in humans is unknown. In the present study, we investigated the impact of atazanavir-induced (unconjugated) hyperbilirubinemia on antioxidant capacity, inflammation, and vascular dysfunction in human experimental endotoxemia. A …
However, its impact during acute inflammation in humans is unknown. In the present study, we investigated the impact of atazanavir-in …
2,075 results

Searches related to "atazanavir"